Details for Patent: 12,329,750
✉ Email this page to a colleague
Which drugs does patent 12,329,750 protect, and when does it expire?
Patent 12,329,750 protects UBRELVY and is included in one NDA.
This patent has forty-one patent family members in thirteen countries.
Summary for Patent: 12,329,750
| Title: | Treatment of migraine |
| Abstract: | The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors. |
| Inventor(s): | Joel M. Trugman, Ramesh BOINPALLY, Abhijeet Jakate, Michelle Finnegan |
| Assignee: | Allergan Pharmaceuticals International Ltd |
| Application Number: | US18/924,415 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,329,750
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A BCRP AND/OR P-GP ONLY INHIBITOR | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,329,750
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015214502 | ⤷ Start Trial | |||
| Australia | 2019226239 | ⤷ Start Trial | |||
| Australia | 2021245229 | ⤷ Start Trial | |||
| Australia | 2021409718 | ⤷ Start Trial | |||
| Australia | 2023258317 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
